Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

[Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa].

Djordjević Z, Gajović O, Mijailović Z, Ilić A, Stolić R.

Srp Arh Celok Lek. 2013 Sep-Oct;141(9-10):640-7. Serbian.

2.

Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.

Onguru P, Erbay A, Bodur H, Baran G, Akinci E, Balaban N, Cevik MA.

J Korean Med Sci. 2008 Dec;23(6):982-7. doi: 10.3346/jkms.2008.23.6.982. Epub 2008 Dec 24.

3.

Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.

Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA.

Antimicrob Agents Chemother. 2002 Mar;46(3):854-8.

4.

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.

Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Romand J, Huber O, Ambrosetti P, Praz G, Lew D, Bille J, Glauser MP, Cometta A.

Antimicrob Agents Chemother. 1998 Nov;42(11):2966-72. Erratum in: Antimicrob Agents Chemother 1999 Mar;43(3):726.

5.

Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.

Mokaddas EM, Sanyal SC.

J Chemother. 1999 Apr;11(2):93-6.

PMID:
10326738
6.

Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.

Mimoz O, Elhelali N, Léotard S, Jacolot A, Laurent F, Samii K, Petitjean O, Nordmann P.

J Antimicrob Chemother. 1999 Jul;44(1):91-7.

PMID:
10459815
7.

Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.

Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW.

Clin Infect Dis. 2008 Mar 15;46(6):862-7. doi: 10.1086/528712.

PMID:
18279040
9.

Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital.

Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, MacDougall C, Jewesson P.

Diagn Microbiol Infect Dis. 1998 Jun;31(2):355-68.

PMID:
9635910
10.

Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.

López-Dupla M, Martínez JA, Vidal F, Almela M, Soriano A, Marco F, López J, Olona M, Mensa J.

Am J Infect Control. 2009 Nov;37(9):753-8. doi: 10.1016/j.ajic.2009.02.003. Epub 2009 May 31.

PMID:
19487049
11.
12.

Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.

Cotrina-Luque J, Gil-Navarro MV, Acosta-García H, Alfaro-Lara ER, Luque-Márquez R, Beltrán-García M, Bautista-Paloma FJ.

Int J Clin Pharm. 2016 Feb;38(1):70-9.

PMID:
26474861
13.

Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.

DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H.

Antimicrob Agents Chemother. 2005 Aug;49(8):3217-21.

14.
15.

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.

Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, Prokocimer P, Friedland I.

Curr Med Res Opin. 2008 Jul;24(7):2113-26. doi: 10.1185/03007990802179255 . Epub 2008 Jun 11.

PMID:
18549664
16.

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Lodise TP Jr, Lomaestro B, Drusano GL.

Clin Infect Dis. 2007 Feb 1;44(3):357-63. Epub 2007 Jan 2.

PMID:
17205441
17.

The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation.

Ozkiris A, Evereklioglu C, Esel D, Akgün H, Göktas S, Erkiliç K.

Curr Eye Res. 2005 Jan;30(1):13-9.

PMID:
15875360
18.

The use of piperacillin-tazobactam coated tympanostomy tubes against ciprofloxacin-resistant Pseudomonas biofilm formation: an in vitro study.

Jang CH, Park H, Cho YB, Choi CH, Park IY.

Int J Pediatr Otorhinolaryngol. 2009 Feb;73(2):295-9. doi: 10.1016/j.ijporl.2008.10.020. Epub 2008 Dec 17.

PMID:
19095310
19.

Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.

Pillay T, Pillay DG, Adhikari M, Sturm AW.

Am J Perinatol. 1998 Jan;15(1):47-51.

PMID:
9475688
20.

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.

Alvarez-Lerma F, Insausti-Ordeñana J, Jordá-Marcos R, Maraví-Poma E, Torres-Martí A, Nava J, Martínez-Pellús A, Palomar M, Barcenilla F; Spanish Collaborative Group for the Study of Severe Infections.

Intensive Care Med. 2001 Mar;27(3):493-502.

PMID:
11355117

Supplemental Content

Support Center